Payment overview · 2025
General Payments
$1,049.63
38 reported records · 16 companies
Healthcare provider profile · identity verified
Mustafa Mohammed Moazam, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EL PASO, TX · NPI 1306987474
Verified facts
What the public records show
CMS Open Payments records show Mustafa Mohammed Moazam, MD received $1,049.63 in general payments during 2025 across 38 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Nurtec Odt, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 615 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 614 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 427 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $215.34 | 20.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $164.21 | 15.6% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $163.02 | 15.5% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $80.57 | 7.7% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $75.81 | 7.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $74.97 | 7.1% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $61.86 | 5.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.30 | 4.2% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $32.02 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.97 | 2.5% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $24.02 | 2.3% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $20.23 | 1.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.74 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.95 | 1.7% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $14.95 | 1.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.67 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,049.63 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $130.80 | 3 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $101.51 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $100.71 | 1 | 2025 |
Source payment records
|
|||||
| Jivi Normalized: jivi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $98.74 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $95.25 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $80.57 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $75.81 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $74.97 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.28 | 3 | 2025 |
Source payment records
|
|||||
| ALPROLIX Normalized: alprolix |
Biological | GENZYME CORPORATION | $61.86 | 2 | 2025 |
Source payment records
|
|||||
| ALTUVIIIO Normalized: altuviiio |
Biological | GENZYME CORPORATION | $61.86 | 2 | 2025 |
Source payment records
|
|||||
| QFITLIA Normalized: qfitlia |
Drug | GENZYME CORPORATION | $61.86 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.41 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $32.02 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.97 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| Alhemo Normalized: alhemo |
Drug | Novo Nordisk Inc | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| Esperoct Normalized: esperoct |
Biological | Novo Nordisk Inc | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 615 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 614 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
81 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
615 | 181 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
614 | 165 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
114 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
258 | 62 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
427 | 106 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
118 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
169 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2357 | 727 |
| Alendronate Sodium | Alendronate Sodium | 1678 | 528 |
| Metformin Hcl | Metformin Hcl | 1437 | 417 |
| Lisinopril | Lisinopril | 1386 | 418 |
| Amlodipine Besylate | Amlodipine Besylate | 1336 | 390 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1095 | 284 |
| Losartan Potassium | Losartan Potassium | 931 | 275 |
| Gabapentin | Gabapentin | 844 | 244 |
| Tamsulosin Hcl | Tamsulosin Hcl | 775 | 243 |
| Montelukast Sodium | Montelukast Sodium | 760 | 226 |
| Omeprazole | Omeprazole | 760 | 219 |
| Farxiga | Dapagliflozin Propanediol | 615 | 181 |
| Jardiance | Empagliflozin | 614 | 165 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 585 | 213 |
| Baclofen | Baclofen | 581 | 208 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 572 | 201 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 546 | 178 |
| Acarbose | Acarbose | 543 | 191 |
| Hydrochlorothiazide | Hydrochlorothiazide | 499 | 154 |
| Folic Acid | Folic Acid | 496 | 167 |
| Famotidine | Famotidine | 495 | 156 |
| Pantoprazole Sodium | Pantoprazole Sodium | 491 | 172 |
| Azithromycin | Azithromycin | 484 | 328 |
| Sertraline Hcl | Sertraline Hcl | 480 | 129 |
| Trazodone Hcl | Trazodone Hcl | 470 | 135 |
| Fluticasone Propionate | Fluticasone Propionate | 450 | 203 |
| Carvedilol | Carvedilol | 433 | 133 |
| Prednisone | Prednisone | 430 | 266 |
| Diclofenac Sodium | Diclofenac Sodium | 429 | 172 |
| Ozempic | Semaglutide | 427 | 106 |
| Ibuprofen | Ibuprofen | 378 | 165 |
| Glimepiride | Glimepiride | 374 | 113 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 353 | 93 |
| Finasteride | Finasteride | 335 | 99 |
| Furosemide | Furosemide | 311 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 311 | 89 |
| Buspirone Hcl | Buspirone Hcl | 294 | 77 |
| Clopidogrel | Clopidogrel Bisulfate | 289 | 75 |
| Memantine Hcl | Memantine Hcl | 278 | 85 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 272 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 267 | 76 |
| Trulicity | Dulaglutide | 258 | 62 |
| Alprazolam | Alprazolam | 257 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 255 | 79 |
| Fluoxetine Hcl | Fluoxetine Hcl | 253 | 60 |
| Tramadol Hcl | Tramadol Hcl | 244 | 75 |
| Meloxicam | Meloxicam | 237 | 84 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 233 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 230 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 208 | 55 |
| Sucralfate | Sucralfate | 202 | 68 |
| Glipizide | Glipizide | 199 | 58 |
| Clonazepam | Clonazepam | 188 | 33 |
| Meclizine Hcl | Meclizine Hcl | 186 | 81 |
| Mirtazapine | Mirtazapine | 181 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 180 | 34 |
| Simvastatin | Simvastatin | 177 | 50 |
| Oxybutynin Chloride | Oxybutynin Chloride | 170 | 58 |
| Eliquis | Apixaban | 169 | 48 |
| Chlorthalidone | Chlorthalidone | 163 | 59 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 160 | 124 |
| Spironolactone | Spironolactone | 154 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 148 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 146 | 47 |
| Rivastigmine | Rivastigmine Tartrate | 146 | 35 |
| Ezetimibe | Ezetimibe | 144 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 139 | 35 |
| Mupirocin | Mupirocin | 138 | 89 |
| Clotrimazole | Clotrimazole | 129 | 78 |
| Lidocaine | Lidocaine | 122 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 121 | 38 |
| Rybelsus | Semaglutide | 118 | 33 |
| Lamotrigine | Lamotrigine | 117 | 26 |
| Mounjaro | Tirzepatide | 114 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 107 | 86 |
| Januvia | Sitagliptin Phosphate | 95 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 33 |
| Fluconazole | Fluconazole | 89 | 67 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 87 | 22 |
| Allopurinol | Allopurinol | 83 | 28 |
| Celecoxib | Celecoxib | 82 | 23 |
| Linzess | Linaclotide | 81 | 31 |
| Vascepa | Icosapent Ethyl | 80 | 30 |
| Dapagliflozin | Dapagliflozin Propanediol | 78 | 49 |
| Donepezil Hcl | Donepezil Hcl | 78 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 77 | 42 |
| Pregabalin | Pregabalin | 77 | 24 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 73 | 22 |
| Cephalexin | Cephalexin | 73 | 60 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 73 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 69 | 30 |
| Naproxen | Naproxen | 69 | 32 |
| Estradiol | Estradiol | 68 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 26 |
| Pentoxifylline | Pentoxifylline | 65 | 23 |
| Humalog Kwikpen U-100 | Insulin Lispro | 64 | 28 |
| Potassium Chloride | Potassium Chloride | 63 | 15 |
| Entresto | Sacubitril/Valsartan | 61 | 16 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 61 | 17 |
| Fenofibrate | Fenofibrate,micronized | 59 | 21 |
| Enalapril Maleate | Enalapril Maleate | 57 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 56 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 45 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 54 | suppressed |
| Hydrocortisone | Hydrocortisone | 54 | 34 |
| Prazosin Hcl | Prazosin Hcl | 54 | 17 |
| Xarelto | Rivaroxaban | 52 | 14 |
| Amoxicillin | Amoxicillin | 51 | 43 |
| Myrbetriq | Mirabegron | 51 | 16 |
| Oxcarbazepine | Oxcarbazepine | 51 | 15 |
| Lactulose | Lactulose | 49 | 26 |
| Premarin | Estrogens, Conjugated | 49 | 24 |
| Levetiracetam | Levetiracetam | 48 | 17 |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 47 | 14 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 46 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 16 |
| Icosapent Ethyl | Icosapent Ethyl | 44 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 15 |
| Metronidazole | Metronidazole | 44 | 32 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 44 | 23 |
| Benazepril Hcl | Benazepril Hcl | 43 | 12 |
| Ketoconazole | Ketoconazole | 43 | 16 |
| Armour Thyroid | Thyroid,pork | 41 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 40 | 21 |
| Ciclopirox | Ciclopirox | 40 | 19 |
| Clonidine Hcl | Clonidine Hcl | 40 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 40 | 16 |
| Topiramate | Topiramate | 39 | suppressed |
| Fenofibrate | Fenofibrate | 38 | 11 |
| Levofloxacin | Levofloxacin | 38 | 35 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 24 |
| Bupropion Xl | Bupropion Hcl | 36 | 12 |
| Metformin Hcl Er | Metformin Hcl | 36 | 15 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 36 | 31 |
| Aimovig Autoinjector | Erenumab-Aooe | 35 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 34 | 22 |
| Ondansetron Odt | Ondansetron | 34 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 28 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 11 |
| Lovastatin | Lovastatin | 33 | suppressed |
| Metolazone | Metolazone | 33 | 12 |
| Nifedipine Er | Nifedipine | 33 | 11 |
| Risperidone | Risperidone | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | 12 |
| Atenolol | Atenolol | 32 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 29 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Xifaxan | Rifaximin | 28 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 22 | 15 |
| Prolia | Denosumab | 22 | 15 |
| Torsemide | Torsemide | 22 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | 12 |
| Ramipril | Ramipril | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 13 |
| Humalog | Insulin Lispro | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | 11 |
| Temazepam | Temazepam | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 15 |
| Movantik | Naloxegol Oxalate | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | 13 |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Desvenlafaxine Er | Desvenlafaxine | 17 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | 11 |
| Dutasteride | Dutasteride | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Clozapine | Clozapine | 13 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Gattex | Teduglutide | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 13 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Propylthiouracil | Propylthiouracil | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | 11 |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,049.63 · 38 records | AstraZeneca Pharmaceuticals LP | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AIRSUPRA, ALPROLIX, ALTUVIIIO, Alhemo, BREZTRI, CAPLYTA, Esperoct, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, INGREZZA, JARDIANCE, Jivi, Kerendia, NEFFY, NURTEC ODT, QFITLIA, REXULTI, REZDIFFRA, The Cologuard Plus Collection Kit, VRAYLAR, ZAVZPRET | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error